FDA Initiates AI-Driven Initiative to Accelerate Clinical Trials
The FDA is embarking on a new initiative aimed at utilizing artificial intelligence to monitor clinical trials in real time, potentially reducing the duration between trial phases.
Editorial Staff
1 min read
Updated 11 days ago
The FDA has announced a new effort to enhance the efficiency of clinical trials by incorporating artificial intelligence technologies. This initiative is expected to facilitate real-time monitoring of trials.
By leveraging AI, the FDA aims to shorten the time intervals between different phases of clinical trials, which could lead to faster access to new treatments for patients.
This move reflects a growing trend in the healthcare sector to adopt innovative technologies to streamline processes and improve outcomes in clinical research.